News

Iomai Acquisition granted clearance by US Authorities

Iomai Acquisition granted clearance by US Authorities

» Definitive proxy statement filed on July 10, 2008; Closing...

Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU

Vienna (Austria), July 09, 2008 – Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal...

Nabriva Therapeutics Announces Appointment of New CEO

Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed...

The Centre of Innovation & Technology of the City of Vienna supports 7-Tesla project at MUV/General Hospita...

The Centre of Innovation & Technology of the City of Vienna supports 7-Tesla project at MUV/General Hospital of Vienna...

Best of Biotech business plan - the winners

Best of Biotech business plan

- the winners

>> New antibiotic from Graz most impresses the jury

Earlybird Venture Capital leads Investiment in Miracor

Earlybird announces the completion of a Series A financing round of € 6 million in Miracor GmbH based in Vienna. Miracor...

Sanochemia: US patent granted for the formulation and use of the active pharmaceutical ingredient PVP hyper...

Sanochemia: US patent granted for the formulation and use of the active pharmaceutical ingredient PVP hypericin

Intercell - Licensure application for Japanese Encephalitis vaccine submitted to Canadian Division of Biolo...

Intercell - Licensure application for Japanese Encephalitis vaccine submitted to Canadian Division of Biologics and...

Start of phase I study for pandemic influenza vaccine

- The Viennese company Avir Green Hills Biotechnology developed a new intranasal influenza vaccine generation


- First...

Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with...

Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea...

Intercell granted Early Termination of HSR Waiting Period for Iomai-Acquisition

Vienna (Austria), June 5, 2008 – Intercell AG (VSE: ICLL) today announced that it has received notice that the U.S....

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on then-current expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? Just send your contributions to news(at)lisavienna.at.